Business
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
Kelly Cloonan·Wall Street Journal·October 30, 2026
The pharmaceutical company boosted its profit outlook for the year, and raised its quarterly dividend as both third-quarter results and full-year guidance came in above expectations.
Read the full story at Wall Street Journal →